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pectoral nerve block to anaesthetise the median part of
chest wall. It is possible that in addition to no effect on
QoR, the pectoral nerve block did not decrease postop-
erative pain scores, and lower visual analogue score scores
in the pectoral nerve group resulted from earlier admin-
istration of rescue analgesics in this group.
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Editor,
Following delivery, active management of the third stage
of labour is an effective strategy to prevent postpartum
blood loss, the major cause of avoidable maternal mortal-
ity. Importantly, there is a lack of consensus amongst
obstetric societies regarding the dosing regimens for
oxytocin prophylaxis, with only the British Guidelines
making a dose recommendation, advising routine
administration of 5 IU oxytocin.1 However, anaesthetists
are increasingly aiming for exact physiological control by
administering lower doses.2
Efficacy studies that aimed to assess the minimum effec-
tive dose in 90% of the population for oxytocin bolus3–5
and an infusion,6,7 all found that a low dose of oxytocin is
sufficient to initiate adequate uterine tone for nonlabour-
ing and labouring women undergoing caesarean section.
This evidence questions the use of a 5 IU bolus for
initiating adequate uterine tone.
However, effectiveness studies are required that examine
the use of low-dose oxytocin under real-world conditions
as efficacy trials examining dose–responses may overes-
timate an intervention’s effect.3–7 Administering a too
low dose may result in uterine atony, which can deterio-
rate into a major obstetric haemorrhage risking severe
maternal morbidity. Moreover, a study that compared
four national guidelines for the prevention and manage-
ment of postpartum haemorrhage identified a need, not
only for stronger evidence, but also for more consistent
synthesis of the available evidence used to develop
guidelines and recommendations, given that obstetric
haemorrhage is the leading cause of maternal mortality.1
To address the uncertainty on the effectiveness of low-dose
oxytocin, we sought to undertake a systematic review and
meta-analysis of data from randomised controlled trials
(RCTs). We examined the effectiveness of prophylactic
low-dose oxytocin protocols (<5 IU) compared with 5 IU
(deliveredas abolus alone,orbolus andcontinuous infusion,
or continuous infusion alone) on the volume of blood loss
in women undergoing elective caesarean section.
A systematic review of RCTs from 1946 until March 2017
was conducted according to Preferred Reporting Items
for Systematic Reviews andMeta-analyses and an a priori
designed protocol. Two independent reviewers
(N.C.S.T., D.S.P.) performed a systematic search in
PubMed, EMBASE, CENTRAL, CINAHL and Web
of Science, and screened the title and abstract of all
articles obtained from the search. A research librarian
assisted with constructing the search strategy, which
combined all synonyms regarding the intervention, ‘oxy-
tocin’ and the domain, ‘caesarean section’ (Supplemen-
tary material 1, http://links.lww.com/EJA/A160). No
limitations were applied to the search. Reference lists
from identified studies, associated with the most re-
trieved citations, were hand-searched to increase the
sensitivity of the search. Finally, a search of trial registries
including the Australian New Zealand Clinical Trials
Registry, ClinicalTrials.gov and the International Clini-
cal Trials Platform was conducted.
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Full-length publications of RCTs of patients undergo-
ing elective caesarean section were accepted for sys-
tematic review if they compared 5 IU oxytocin with less
than 5 IU oxytocin prophylaxis at delivery (whether
delivered as a bolus dose, a bolus and continuous
infusion or a continuous infusion alone), and reported
postpartum blood loss. For the standard-dose group,
the total oxytocin dose administered should not exceed
5 IU. For the low-dose group, the total oxytocin dose
should be less than 5 IU. Studies were excluded if the
population was nonhuman patients who were not un-
dergoing caesarean section, and oxytocin was not in-
vestigated. The remaining studies were reviewed in
full. There were no restrictions on the language or
follow-up duration.
Theprimary outcomewas themean volumeof postpartum
blood loss (measured or estimated). The following sec-
ondary outcomes were examined. Major obstetric blood
loss (measured or estimated blood loss of more than
1000ml); the use of additional therapeutic uterotonics to
supplement the oxytocin intervention (Yes/No); hypoten-
sion (a decrease inmean arterial pressure of at least 10% or
10mmHg); vomiting (the ejection of stomach content);
nausea (assessed bydirectly questioning the patient) (Any/
None); adequate uterine tone (uterine tone assessed as
adequate by the attending obstetrician) (Yes/No).
A risk of bias assessment and also a data extraction
and statistical analysis plan was specified a priori for
meta-analysis of the data but was not enacted due to
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lack of eligible studies and, therefore, is not detailed
here (Supplemental material 1, http://links.lww.com/
EJA/A160).
The literature search returned 10 383 studies (Fig. 1,
Supplemental material 1, http://links.lww.com/EJA/
A160) with 2690 studies excluded due to duplication,
resulting in 7693 studies that had been checked for title
and abstract. Another 7681 were excluded resulting in 12
studies for full-text review. After full-text review, all 12
were excluded. As no study matched our inclusion crite-
ria, we were not able to analyse our postulated primary
outcome criteria.
To our knowledge, this is the first systematic review of
RCTs that sought to determine the effectiveness of
lowering the oxytocin dose on postpartum blood loss in
women undergoing elective caesarean section. Remark-
ably, despite an exhaustive search, no trial investigated
exactly the oxytocin regimes under investigation; specifi-
cally, the effectiveness of prophylactically administering
less than 5 IU doses in comparison with guideline recom-
mended 5 IU on postpartum blood loss. Overall, there
was no information for or against the effectiveness of 5 IU
oxytocin versus a lower dose on postpartum blood loss.
Several practice surveys have identified significant varia-
tion in prophylactic oxytocin regimens (bolus and infu-
sion) used at caesarean section. A national survey of
oxytocin use showed that 52% of anaesthesia depart-
ments administered between 1 and 3 IU; 21% gave
between 5 and 9 IU; 12% gave 10 IU; and 2% adminis-
tered between 12 and 40 IU prophylactically at caesarean
section.8 This suggests that there is a lack of consensus
amongst anaesthetists regarding the optimal oxytocin
dose regimen and potentially implies a lack of confidence
in the evidence supporting effective oxytocin dosing.
Notably, many guideline recommendations for the pre-
vention and management of postpartum haemorrhage
(16/28; 57%), including the 5 IU dose recommendation,
are backed up with weak evidence,1 altogether this
paucity of evidence suggests that the perfect oxytocin
dose regimen is open for debate.
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